Thanh-Nhat Pham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Thanh-Nhat Pham has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
Corine Girard-Thernier
PEPITE EA4267, FHU INCREASE, Univ. Bourgogne Franche-Comté, F-25000 Besançon, France
2 shared publications- Marc Pudlo
Université de Franche-Comté, EFS, INSERM, RIGHT (UMR 1098), F-25000 Besançon, France
2 shared publications Simon Bordage
PEPITE EA4267, Univ. Bourgogne Franche-Comté, Besançon, France
2 shared publications- Abdelfattah Faouzi
Center for Clinical Pharmacology, St. Louis College of Pharmacy and Washington University School of Medicine, St. Louis, MO 63131, USA
1 shared publication Ahmed ElHady
Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C2.3, D-66123 Saarbrücken, Germany
1 shared publicationAlexandra Dassonville‐Klimpt
Université de Picardie Jules Verne, AGIR: Agents Infectieux, Résistance et Chimiothérapie, Amiens, France
1 shared publication
Latest Publications
- 2 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Recherche de nouveaux inhibiteurs d'arginase, d'origine naturelle et hémisynthétique, inspirés de l'acide chlorogénique et du picéatannol
L’inhibition de l’arginase a été montrée pour le traitement de la dysfonction endothéliale dans plusieurs pathologies. Des inhibiteurs sont actuellement commercialisés (nor-NOHA, ABH et BEC) mais en dépit de leur potentiel, ils sont incompatibles avec un usage médical per os. L’obtention de nouveaux inhibiteurs reste donc un challenge pour le développement de candidats médicaments. La source naturelle et la voie hémisynthétique notamment, restent encore des axes peu explorés. Visant d’abord le développement d’un test fiable et reproductible pour l’évaluation de la capacité inhibitrice de molécules, nous avons optimisé un test existant et mis en place un essai colorimétrique miniaturisé et partiellement automatisé, utilisant une arginase mammifère commerciale, purifiée de foie de bœuf. Ce test a été validé via l’utilisation d’inhibiteurs de référence (CI50 : nor-NOHA 1,7 μM / BEC 3,3 μM), avant d’être utilisé pour l’évaluation biologique d’une série de polyphénols naturels, mettant en évidence les potentialités inhibitrices de l’acide chlorogénique (acide caféoylquinique / CI50 10,6 μM) et du picéatannol (stilbène / CI50 12,1 µM). Des études de cinétique enzymatique ont montré que l’inhibition était réversible et compétitive tandis que des études de docking moléculaire ont montré l’intérêt de la partie caféique pour l’activité inhibitrice. Nous nous sommes alors focalisés sur l’obtention de dérivés d’hémisynthèse. Dix-neuf dérivés dérivés cinnamides ont été préparés ainsi qu’une série de cinq composés esters. Les études de relation structure-activité ont montré le rôle important du groupement catéchol pour l’activité de ces molécules. Le composé (E)-N-(2-phényléthyl)-3,4-dihydroxycinnamide ou « caffeic acid phenyl amide » (CAPA) a présenté la meilleure activité (CI50 6,9 μM). C’est un inhibiteur réversible et compétitif de l’arginase étudiée et ses études de docking avec le site catalytique de l’enzyme ont confirmé les interactions du catéchol avec des résidus conservés du site actif et les ions manganèse. La préparation des dérivés de stilbènes cibles n’a pas été couronnée de succès mais grâce à des collaborations, deux stilbènes naturels, l’astringine et le picéide, ainsi qu’une série de stilbénoïdes synthétiques ont pu être évalués. Cependant, aucun de ces composés n’a révélé d’activité intéressante.Finalement, notre projet de thèse a mis en évidence les activités prometteuses de deux composés naturels, l’acide chlorogénique et le picéatannol, ainsi que celle d’un composé hémisynthétique dérivés cinnamide de l’acide caféique (CAPA). Ces molécules ont en commun, au niveau structural, la présence d’une partie 3,4-dhydroxycinnamique (caféoyle), révélant l’intérêt de ce motif pour la conception d’autres molécules à capacité inhibitrice d’arginase. Ces résultats obtenus in silico et in vitro sur l’arginase bovine b-ARG I devront être confirmés sur l’arginase humaine h-ARG avant d’envisager d’éventuelles études in vivo pour ces candidats-médicaments potentiels.
- 2 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Recherche de nouveaux inhibiteurs d'arginase, d'origine naturelle et hémisynthétique, inspirés de l'acide chlorogénique et du picéatannol
L’inhibition de l’arginase a été montrée pour le traitement de la dysfonction endothéliale dans plusieurs pathologies. Des inhibiteurs sont actuellement commercialisés (nor-NOHA, ABH et BEC) mais en dépit de leur potentiel, ils sont incompatibles avec un usage médical per os. L’obtention de nouveaux inhibiteurs reste donc un challenge pour le développement de candidats médicaments. La source naturelle et la voie hémisynthétique notamment, restent encore des axes peu explorés. Visant d’abord le développement d’un test fiable et reproductible pour l’évaluation de la capacité inhibitrice de molécules, nous avons optimisé un test existant et mis en place un essai colorimétrique miniaturisé et partiellement automatisé, utilisant une arginase mammifère commerciale, purifiée de foie de bœuf. Ce test a été validé via l’utilisation d’inhibiteurs de référence (CI50 : nor-NOHA 1,7 μM / BEC 3,3 μM), avant d’être utilisé pour l’évaluation biologique d’une série de polyphénols naturels, mettant en évidence les potentialités inhibitrices de l’acide chlorogénique (acide caféoylquinique / CI50 10,6 μM) et du picéatannol (stilbène / CI50 12,1 µM). Des études de cinétique enzymatique ont montré que l’inhibition était réversible et compétitive tandis que des études de docking moléculaire ont montré l’intérêt de la partie caféique pour l’activité inhibitrice. Nous nous sommes alors focalisés sur l’obtention de dérivés d’hémisynthèse. Dix-neuf dérivés dérivés cinnamides ont été préparés ainsi qu’une série de cinq composés esters. Les études de relation structure-activité ont montré le rôle important du groupement catéchol pour l’activité de ces molécules. Le composé (E)-N-(2-phényléthyl)-3,4-dihydroxycinnamide ou « caffeic acid phenyl amide » (CAPA) a présenté la meilleure activité (CI50 6,9 μM). C’est un inhibiteur réversible et compétitif de l’arginase étudiée et ses études de docking avec le site catalytique de l’enzyme ont confirmé les interactions du catéchol avec des résidus conservés du site actif et les ions manganèse. La préparation des dérivés de stilbènes cibles n’a pas été couronnée de succès mais grâce à des collaborations, deux stilbènes naturels, l’astringine et le picéide, ainsi qu’une série de stilbénoïdes synthétiques ont pu être évalués. Cependant, aucun de ces composés n’a révélé d’activité intéressante.Finalement, notre projet de thèse a mis en évidence les activités prometteuses de deux composés naturels, l’acide chlorogénique et le picéatannol, ainsi que celle d’un composé hémisynthétique dérivés cinnamide de l’acide caféique (CAPA). Ces molécules ont en commun, au niveau structural, la présence d’une partie 3,4-dhydroxycinnamique (caféoyle), révélant l’intérêt de ce motif pour la conception d’autres molécules à capacité inhibitrice d’arginase. Ces résultats obtenus in silico et in vitro sur l’arginase bovine b-ARG I devront être confirmés sur l’arginase humaine h-ARG avant d’envisager d’éventuelles études in vivo pour ces candidats-médicaments potentiels.
- Open Access
- 17 October 2024
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (1) , 179-199
Design, synthesis, and structure–activity relationship studies of 6 H -benzo[ b ]indeno[1,2- d ]thiophen-6-one derivatives as DYRK1A/CLK1/CLK4/haspin inhibitors
A series of sulfur-containing tetracycles was designed and evaluated for their ability to inhibit protein kinase DYRK1A, a target known to have several potential therapeutic applications including cancers, Down syndrome or Alzheimer's disease. Our medicinal chemistry strategy relied on the design of new compounds using ring contraction/isosteric replacement and constrained analogy of known DYRK1A inhibitors, thus resulting in their DYRK1A inhibitory activity enhancement. Whereas a good inhibitory effect of targeted DYRK1A protein was observed for 5-hydroxy compounds 4i–k (IC50 = 35–116 nM) and the 5-methoxy derivative 4e (IC50 = 52 nM), a fairly good selectivity towards its known DYRK1B off-target was observed for 4k. In addition, the most active compound 4k, having an ATP-competitive mechanism of action, proved to be also a potent inhibitor of CLK1/CLK4 (IC50 = 20 and 26 nM) and, to a lesser extent, of haspin (IC50 = 76 nM) kinases. In silico docking studies within the DYRK1A, CLK1/CLK4 and haspin ATP binding sites were carried out to understand the interactions of our tetracyclic derivatives 4 with these targets. Antiproliferative activities on U87/U373 glioblastoma cell lines of the most potent compound 4k showed a moderate effect (IC50 values between 33 and 46 μM). Microsomal stabilities of the designed compounds 4a–m were also investigated, showing great disparities, depending on benzo[b]thiophene ring 5-substitution.
- 17 October 2024
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (1) , 179-199
Open AccessDesign, synthesis, and structure–activity relationship studies of 6 H -benzo[ b ]indeno[1,2- d ]thiophen-6-one derivatives as DYRK1A/CLK1/CLK4/haspin inhibitors
A series of sulfur-containing tetracycles was designed and evaluated for their ability to inhibit protein kinase DYRK1A, a target known to have several potential therapeutic applications including cancers, Down syndrome or Alzheimer's disease. Our medicinal chemistry strategy relied on the design of new compounds using ring contraction/isosteric replacement and constrained analogy of known DYRK1A inhibitors, thus resulting in their DYRK1A inhibitory activity enhancement. Whereas a good inhibitory effect of targeted DYRK1A protein was observed for 5-hydroxy compounds 4i–k (IC50 = 35–116 nM) and the 5-methoxy derivative 4e (IC50 = 52 nM), a fairly good selectivity towards its known DYRK1B off-target was observed for 4k. In addition, the most active compound 4k, having an ATP-competitive mechanism of action, proved to be also a potent inhibitor of CLK1/CLK4 (IC50 = 20 and 26 nM) and, to a lesser extent, of haspin (IC50 = 76 nM) kinases. In silico docking studies within the DYRK1A, CLK1/CLK4 and haspin ATP binding sites were carried out to understand the interactions of our tetracyclic derivatives 4 with these targets. Antiproliferative activities on U87/U373 glioblastoma cell lines of the most potent compound 4k showed a moderate effect (IC50 values between 33 and 46 μM). Microsomal stabilities of the designed compounds 4a–m were also investigated, showing great disparities, depending on benzo[b]thiophene ring 5-substitution.
- Top Cited PapersOpen Access
- 1 August 2024
- Published by Elsevier in Waste Management
- Vol. 188, 11-38
Exploring industrial lignocellulosic waste: Sources, types, and potential as high-value molecules
- 1 August 2024
- Published by Elsevier in Waste Management
- Vol. 188, 11-38
Top Cited PapersOpen AccessExploring industrial lignocellulosic waste: Sources, types, and potential as high-value molecules
- 22 November 2023
- Published by Elsevier in Drug Discovery Today
- Vol. 29 (1) , 103843
Valorization of biomass polyphenols as potential tyrosinase inhibitors
- 22 November 2023
- Published by Elsevier in Drug Discovery Today
- Vol. 29 (1) , 103843
Valorization of biomass polyphenols as potential tyrosinase inhibitors
- Open Access
Cinnamides Target Leishmania amazonensis Arginase Selectively
Caffeic acid and related natural compounds were previously described as Leishmania amazonensis arginase (L-ARG) inhibitors, and against the whole parasite in vitro. In this study, we tested cinnamides that were previously synthesized to target human arginase. The compound caffeic acid phenethyl amide (CAPA), a weak inhibitor of human arginase (IC50 = 60.3 ± 7.8 μM) was found to have 9-fold more potency against L-ARG (IC50 = 6.9 ± 0.7 μM). The other compounds that did not inhibit human arginase were characterized as L-ARG, showing an IC50 between 1.3–17.8 μM, and where the most active was compound 15 (IC50 = 1.3 ± 0.1 μM). All compounds were also tested against L. amazonensis promastigotes, and only the compound CAPA showed an inhibitory activity (IC50 = 80 μM). In addition, in an attempt to gain an insight into the mechanism of competitive L-ARG inhibitors, and their selectivity over mammalian enzymes, we performed an extensive computational investigation, to provide the basis for the selective inhibition of L-ARG for this series of compounds. In conclusion, our results indicated that the compounds based on cinnamoyl or 3,4-hydroxy cinnamoyl moiety could be a promising starting point for the design of potential antileishmanial drugs based on selective L-ARG inhibitors.
Open AccessCinnamides Target Leishmania amazonensis Arginase Selectively
Caffeic acid and related natural compounds were previously described as Leishmania amazonensis arginase (L-ARG) inhibitors, and against the whole parasite in vitro. In this study, we tested cinnamides that were previously synthesized to target human arginase. The compound caffeic acid phenethyl amide (CAPA), a weak inhibitor of human arginase (IC50 = 60.3 ± 7.8 μM) was found to have 9-fold more potency against L-ARG (IC50 = 6.9 ± 0.7 μM). The other compounds that did not inhibit human arginase were characterized as L-ARG, showing an IC50 between 1.3–17.8 μM, and where the most active was compound 15 (IC50 = 1.3 ± 0.1 μM). All compounds were also tested against L. amazonensis promastigotes, and only the compound CAPA showed an inhibitory activity (IC50 = 80 μM). In addition, in an attempt to gain an insight into the mechanism of competitive L-ARG inhibitors, and their selectivity over mammalian enzymes, we performed an extensive computational investigation, to provide the basis for the selective inhibition of L-ARG for this series of compounds. In conclusion, our results indicated that the compounds based on cinnamoyl or 3,4-hydroxy cinnamoyl moiety could be a promising starting point for the design of potential antileishmanial drugs based on selective L-ARG inhibitors.
- 19 April 2019
- Published by Wiley in Medicinal Research Reviews
- Vol. 39 (6) , 2343-2396
Drug delivery systems designed to overcome antimicrobial resistance
Antimicrobial resistance has emerged as a huge challenge to the effective treatment of infectious diseases. Aside from a modest number of novel anti‐infective agents, very few new classes of antibiotics have been successfully developed for therapeutic use. Despite the research efforts of numerous scientists, the fight against antimicrobial (ATB) resistance has been a longstanding continued effort, as pathogens rapidly adapt and evolve through various strategies, to escape the action of ATBs. Among other mechanisms of resistance to antibiotics, the sophisticated envelopes surrounding microbes especially form a major barrier for almost all anti‐infective agents. In addition, the mammalian cell membrane presents another obstacle to the ATBs that target intracellular pathogens. To negotiate these biological membranes, scientists have developed drug delivery systems to help drugs traverse the cell wall; these are called “Trojan horse” strategies. Within these delivery systems, ATB molecules can be conjugated with one of many different types of carriers. These carriers could include any of the following: siderophores, antimicrobial peptides, cell‐penetrating peptides, antibodies, or even nanoparticles. In recent years, the Trojan horse‐inspired delivery systems have been increasingly reported as efficient strategies to expand the arsenal of therapeutic solutions and/or reinforce the effectiveness of conventional ATBs against drug‐resistant microbes, while also minimizing the side effects of these drugs. In this paper, we aim to review and report on the recent progress made in these newly prevalent ATB delivery strategies, within the current context of increasing ATB resistance.
- 19 April 2019
- Published by Wiley in Medicinal Research Reviews
- Vol. 39 (6) , 2343-2396
Drug delivery systems designed to overcome antimicrobial resistance
Antimicrobial resistance has emerged as a huge challenge to the effective treatment of infectious diseases. Aside from a modest number of novel anti‐infective agents, very few new classes of antibiotics have been successfully developed for therapeutic use. Despite the research efforts of numerous scientists, the fight against antimicrobial (ATB) resistance has been a longstanding continued effort, as pathogens rapidly adapt and evolve through various strategies, to escape the action of ATBs. Among other mechanisms of resistance to antibiotics, the sophisticated envelopes surrounding microbes especially form a major barrier for almost all anti‐infective agents. In addition, the mammalian cell membrane presents another obstacle to the ATBs that target intracellular pathogens. To negotiate these biological membranes, scientists have developed drug delivery systems to help drugs traverse the cell wall; these are called “Trojan horse” strategies. Within these delivery systems, ATB molecules can be conjugated with one of many different types of carriers. These carriers could include any of the following: siderophores, antimicrobial peptides, cell‐penetrating peptides, antibodies, or even nanoparticles. In recent years, the Trojan horse‐inspired delivery systems have been increasingly reported as efficient strategies to expand the arsenal of therapeutic solutions and/or reinforce the effectiveness of conventional ATBs against drug‐resistant microbes, while also minimizing the side effects of these drugs. In this paper, we aim to review and report on the recent progress made in these newly prevalent ATB delivery strategies, within the current context of increasing ATB resistance.
- 1 April 2018
- Published by Elsevier in Drug Discovery Today
- Vol. 23 (4) , 871-878
Research of novel anticancer agents targeting arginase inhibition
- 1 April 2018
- Published by Elsevier in Drug Discovery Today
- Vol. 23 (4) , 871-878
Research of novel anticancer agents targeting arginase inhibition
- 24 October 2016
- Published by Georg Thieme Verlag KG in Planta Medica
- Vol. 83 (07) , 647-653
Investigation of Mammal Arginase Inhibitory Properties of Natural Ubiquitous Polyphenols by Using an Optimized Colorimetric Microplate Assay
Polyphenols are plant secondary metabolites which possess many positive effects on human health. Although these beneficial effects could be mediated through an increase in nitric oxide synthase activity, little is known regarding the inhibitory effect of polyphenols on mammal arginase, an enzyme which competes with nitric oxide synthase for their common substrate, L-arginine. The aim of the present study was to determine the potential of a series of polyphenols as mammalian arginase inhibitors and to identify some structure-activity relationships. For this purpose, we first developed a simple and cost-effective in vitro colorimetric microplate method using commercially-available mammal bovine liver arginase (b-ARG 1). Among the ten tested polyphenolic compounds [chlorogenic acid, piceatannol, resveratrol, (−)-epicatechin, taxifolin, quercetin, fisetin, caffeic acid, quinic acid, and kaempferol], cholorogenic acid and piceatannol exhibited the highest inhibitory activities (IC50 = 10.6 and 12.1 µM, respectively) but were however less active as (S)-(2-Boronoethyl)-L-cysteine (IC50 = 3.3 µM), used as reference compound. Enzyme kinetic studies showed that both chlorogenic acid and piceatannol are competitive arginase inhibitors. Structural data identified the importance of the caffeoyl (3,4-dihydroxycinnamoyl)-part and of the catechol function in the inhibitory activity of the tested compounds. These results identified chlorogenic acid and piceatannol as two potential core structures for the design of new arginase inhibitors. * Simon Bordage and Thanh-Nhat Pham contributed equally to this work.
- 24 October 2016
- Published by Georg Thieme Verlag KG in Planta Medica
- Vol. 83 (07) , 647-653
Investigation of Mammal Arginase Inhibitory Properties of Natural Ubiquitous Polyphenols by Using an Optimized Colorimetric Microplate Assay
Polyphenols are plant secondary metabolites which possess many positive effects on human health. Although these beneficial effects could be mediated through an increase in nitric oxide synthase activity, little is known regarding the inhibitory effect of polyphenols on mammal arginase, an enzyme which competes with nitric oxide synthase for their common substrate, L-arginine. The aim of the present study was to determine the potential of a series of polyphenols as mammalian arginase inhibitors and to identify some structure-activity relationships. For this purpose, we first developed a simple and cost-effective in vitro colorimetric microplate method using commercially-available mammal bovine liver arginase (b-ARG 1). Among the ten tested polyphenolic compounds [chlorogenic acid, piceatannol, resveratrol, (−)-epicatechin, taxifolin, quercetin, fisetin, caffeic acid, quinic acid, and kaempferol], cholorogenic acid and piceatannol exhibited the highest inhibitory activities (IC50 = 10.6 and 12.1 µM, respectively) but were however less active as (S)-(2-Boronoethyl)-L-cysteine (IC50 = 3.3 µM), used as reference compound. Enzyme kinetic studies showed that both chlorogenic acid and piceatannol are competitive arginase inhibitors. Structural data identified the importance of the caffeoyl (3,4-dihydroxycinnamoyl)-part and of the catechol function in the inhibitory activity of the tested compounds. These results identified chlorogenic acid and piceatannol as two potential core structures for the design of new arginase inhibitors. * Simon Bordage and Thanh-Nhat Pham contributed equally to this work.
- Open Access
- 29 September 2016
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 17 (10) , 1656
Cinnamide Derivatives as Mammalian Arginase Inhibitors: Synthesis, Biological Evaluation and Molecular Docking
Arginases are enzymes that are involved in many human diseases and have been targeted for new treatments. Here a series of cinnamides was designed, synthesized and evaluated in vitro and in silico for their inhibitory activity against mammalian arginase. Using a microassay on purified liver bovine arginase (b-ARG I), (E)-N-(2-phenylethyl)-3,4-dihydroxycinnamide, also named caffeic acid phenylamide (CAPA), was shown to be slightly more active than our natural reference inhibitor, chlorogenic acid (IC50 = 6.9 ± 1.3 and 10.6 ± 1.6 µM, respectively) but it remained less active that the synthetic reference inhibitor Nω-hydroxy-nor-l-arginine nor-NOHA (IC50 = 1.7 ± 0.2 µM). Enzyme kinetic studies showed that CAPA was a competitive inhibitor of arginase with Ki = 5.5 ± 1 µM. Whereas the activity of nor-NOHA was retained (IC50 = 5.7 ± 0.6 µM) using a human recombinant arginase I (h-ARG I), CAPA showed poorer activity (IC50 = 60.3 ± 7.8 µM). However, our study revealed that the cinnamoyl moiety and catechol function were important for inhibitory activity. Docking results on h-ARG I demonstrated that the caffeoyl moiety could penetrate into the active-site pocket of the enzyme, and the catechol function might interact with the cofactor Mn2+ and several crucial amino acid residues involved in the hydrolysis mechanism of arginase. The results of this study suggest that 3,4-dihydroxycinnamides are worth being considered as potential mammalian arginase inhibitors, and could be useful for further research on the development of new arginase inhibitors.
- 29 September 2016
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 17 (10) , 1656
Open AccessCinnamide Derivatives as Mammalian Arginase Inhibitors: Synthesis, Biological Evaluation and Molecular Docking
Arginases are enzymes that are involved in many human diseases and have been targeted for new treatments. Here a series of cinnamides was designed, synthesized and evaluated in vitro and in silico for their inhibitory activity against mammalian arginase. Using a microassay on purified liver bovine arginase (b-ARG I), (E)-N-(2-phenylethyl)-3,4-dihydroxycinnamide, also named caffeic acid phenylamide (CAPA), was shown to be slightly more active than our natural reference inhibitor, chlorogenic acid (IC50 = 6.9 ± 1.3 and 10.6 ± 1.6 µM, respectively) but it remained less active that the synthetic reference inhibitor Nω-hydroxy-nor-l-arginine nor-NOHA (IC50 = 1.7 ± 0.2 µM). Enzyme kinetic studies showed that CAPA was a competitive inhibitor of arginase with Ki = 5.5 ± 1 µM. Whereas the activity of nor-NOHA was retained (IC50 = 5.7 ± 0.6 µM) using a human recombinant arginase I (h-ARG I), CAPA showed poorer activity (IC50 = 60.3 ± 7.8 µM). However, our study revealed that the cinnamoyl moiety and catechol function were important for inhibitory activity. Docking results on h-ARG I demonstrated that the caffeoyl moiety could penetrate into the active-site pocket of the enzyme, and the catechol function might interact with the cofactor Mn2+ and several crucial amino acid residues involved in the hydrolysis mechanism of arginase. The results of this study suggest that 3,4-dihydroxycinnamides are worth being considered as potential mammalian arginase inhibitors, and could be useful for further research on the development of new arginase inhibitors.